Suven Life gets drug patents in Russia, Australia
New Delhi, May 27 (UNI) Drug firm Suven Life Sciences Ltd today said it has received two product patents in Russia and Australia for two of its new chemical entities (NCEs) used in the treatment of disorders associated with neuro-degenerative diseases.
The company said in a statement that the patents for the drug candidates, which target 18-billion-dollar potential market globally, are valid till 2023.
UNI SG ARB DS1328
More From
-
Iran Rejects Trump’s Ceasefire Claim: Tehran Denies Talks, Calls It ‘US Retreat’ -
Tamil Nadu Opinion Poll: ANS Projects DMK Winning In 180 Seats In 234-Member Assembly -
Chennai Gold Silver Rate Today, 23 March 2026: Gold Price Hits 4-Month Low, Silver Slumps Amid Market Volatily -
Gold Silver Rate Today, 23 March 2026: City-Wise Prices, MCX Gold And Silver Extend March Weakness -
Passengers Evacuated After Air Canada Plane Reportedly Hits Fire Truck At LaGuardia -
Trump Announces 5-Day Strike Pause With Iran Amid Escalating West Asia War -
Oil Prices Slide, Stocks Recover Soon After Trump’s 'Ceasefire' Announcement -
Iran vs US-Israel War Halted? Breakthrough or Breather Before a Bigger Conflict -
Hyderabad Gold Silver Rate Today, 23 March 2026: Check Latest Gold And Silver Prices In The City -
Why Share Market Crashing Today: ₹13 Lakh Crore Wiped Out in Just 1 Hour, What Triggered Panic? -
“Thank You, India”: Iran Thanks Kashmir For Donations Of Gold, Cash And Livestock -
Why Indian Stock Market Is Down Today? Top Factors Behind ₹10 Lakh Crore Wealth Erosion
Click it and Unblock the Notifications
Sign in with Google